Gary Allenby BSc, PhD

Gary After completing a Ph.D. in reproductive toxicology he post-doc’ed at Hoffmann La Roche U.S.A, studying the pharmacology of retinoid biology. He returned to the U.K. into Lead Generation at Glaxo Wellcome, developing cell-based assays and working with vendors to validate new technologies for screening.

In 2000 he joined Hit Identification at AstraZeneca, developing assays for respiratory and inflammatory disease and continuing to work with vendors. In 2011 he became a founding entrepreneur of Aurelia Bioscience, a pre-clinical contract research organisation specialising in the development of cell-based assays for compound and biologics screening. Our unique selling point is the development of more physiological phenotypic assays.